NCT05821959View on ClinicalTrials.gov

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Sensorineural Hearing Loss, Bilateral
Interventions
COMBINATION_PRODUCT

AAVAnc80-hOTOF via Akouos Delivery Device

AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.

COMBINATION_PRODUCT

AAVAnc80-hOTOF via Akouos Delivery Device

AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time bilateral intracochlear administration using the Akouos Delivery Device.

Trial Locations (8)

100

RECRUITING

National Taiwan University Hospital, Taipei

19146

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

37232

RECRUITING

Vanderbilt Bill Wilkerson Center, Nashville

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

52242

RECRUITING

University of Iowa, Iowa City

02115

RECRUITING

Boston Children's Hospital, Boston

M5G 1X8

RECRUITING

The Hospital for Sick Children [email protected] +1 (416) 813 6683, Toronto

NW1 2PG

RECRUITING

University College London, London

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Akouos, Inc.

INDUSTRY